Procept BioRobotics reports Q1 EPS (56c), consensus (55c)

Reports Q1 revenue $83.1M, consensus $80.3M. The Company “recently received FDA clearance of its second-generation FirstAssist AI(TM) software, an advancement in personalized, image-guided planning for Aquablation therapy. This milestone further strengthens the capabilities of the HYDROS robotic system, the Company’s next-generation AI-powered platform. The enhanced software enables more precise identification of prostate anatomy and more complete treatment planning to help surgeons plan with greater confidence and consistency.” “Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work,” said Larry Wood, Chief Executive Officer. “We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing. Aquablation(R) users completed approximately 12,200 U.S. procedures in the first quarter of 2026. Handpiece sales were about 95% of procedures, reflecting normalizing field inventory levels. While our recent commercial realignment created some near-term disruption, the team is adapting quickly, and we expect the benefits to build through the year, driving sustained growth and improved profitability.”